Ocyan - My point was that no matter which spend function they moved from and which spend function they moved to it is probably impossible to justify the decrease in trial size for the small increase in final alpha once you take into account that much of the power of the trial is likely to be in the tail.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.